Depomed (DEPO) Misses Q4 EPS by 13c
Tweet
Share
E-mailGet Alerts DEPO Hot Sheet
Price: $7.30 --0%
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.
Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.
For earnings history and earnings-related data on Depomed (DEPO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Symrise AG (SY1:GR) (SYIEY) PT Raised to EUR120 at CFRA
- Deutsche Bank (DB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
